AN2 Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapeutics from its boron chemistry platform, announced it has completed dosing the first single ascending dose cohort in its Phase 1 trial evaluating the safety, tolerability, and pharmacokinetics of oral AN2-502998 in healthy volunteers.

AN2-502998 is a potential curative treatment for chronic Chagas disease. Phase 1 dosing is expected to finish by the end of 2025.

“This is an exciting milestone for our team and the community of patients suffering from chronic Chagas disease, caused by infection with the parasite T. cruzi. AN2-502998 is a promising potential oral cure for chronic Chagas disease, which affects an estimated 6-7 million people worldwide, including approximately 300,000 people in the U.S. and over 100,000 in Europe.

Our studies in nonhuman primates that are naturally infected with T. cruzi have demonstrated AN2-502998’s curative potential and provide a compelling translational rationale for its expected efficacy in humans. Chronic Chagas disease is often asymptomatic, so this significant unmet need has long been overlooked. We are committed to making a change,” said Eric Easom, Co-Founder, Chairman, President, and CEO of AN2 Therapeutics.

“Our recently announced collaboration with the Drugs for Neglected Diseases initiative marks a pivotal step forward as we continue planning for a Phase 2 trial in parallel. Phase 2 potential proof-of-concept data is expected within our cash runway, advancing our commitment to bringing this much needed treatment to patients.”